Bipolar Disorder Therapeutics Market Size and Forecast 2024-2033|AbbVie Inc., Pfizer Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb

Overview and Scope

Bipolar disorder therapeutics refer to medication, including mood stabilizers, antidepressants, antipsychotics, and psychological counseling, to control symptoms. The bipolar disorder therapeutic is used in the treatment and management of bipolar disorders.

Sizing and Forecast

The bipolar disorder therapeutics market size has grown strongly in recent years. It will grow from $7.09 billion in 2023 to $7.53 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rise in medical research and developments, increased healthcare expenditure, rise in prevalence of mental health disorders, rise in patient advocacy.

The bipolar disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $9.46 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing prevalence of bipolar disorder, government initiatives, expansion of healthcare infrastructure, growing adoption of a sedentary lifestyle. Major trends in the forecast period include personalized treatment approaches, digital health integration, innovative medications, preventive interventions, neuroimaging and biomarkers.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

Segmentation & Regional Insights

The bipolar disorder therapeutics market covered in this report is segmented –

1) By Drug Class: Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs, Other Drugs

2) By Mechanism: Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines, Beta-Blockers, Other Mechanisms

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

North America was the largest region in the bipolar disorder therapeutics market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder therapeutics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6736&type=smp

Major Driver Impacting Market Growth

The increase in the prevalence of bipolar disorder is expected to propel the growth of the bipolar disorder therapeutics market going forward. Bipolar disorder refers to a disabling illness that is associated with depressive mood swings and includes symptoms such as irregular sleep, low motivation, and loss of interest in daily activities. Population growth and aging are leading to an increase in the burden of bipolar disorder over time. As a result, an increase in the prevalence of bipolar disorder increases the demand for the bipolar disorder therapeutics market. For instance, according to the Depression and Bipolar Support Alliance, a US-based non-profit association providing support to the patients of depression or bipolar disorder, in 2021, approximately 5.7 million adult Americans which was about 2.6% of the U.S. population were affected by bipolar disorder. The median age of the onset of bipolar disorder is 25 years, and more than two-thirds of people suffering from bipolar disorder had at least one relative with the illness. Therefore, the increase in the prevalence of bipolar disorder is driving the growth of the bipolar disorder therapeutics market.

Key Industry Players

Major companies operating in the bipolar disorder therapeutics market include AbbVie Inc., Pfizer Inc., Astellas Pharma Inc, AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC, Januaryssen Pharmaceuticals, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Validus Pharmaceuticals, Eli Lilly and Company, Gedeon Richter PLC., Sumitomo Pharma Co. Ltd, H. Lundbeck A/S, Janssen Pharmaceuticals, Sanofi S.A., Lundbeck A/S, Allergan plc, Takeda Pharmaceutical Company Limited, Sunovion Pharmaceuticals Inc., Alkermes plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Celon Pharma SA, NeuroRx Inc., IntraCellular Therapies Inc., Sumitomo Pharma Co. Ltd., Vanda Pharmaceuticals Inc., Sage Therapeutics Inc.

The bipolar disorder therapeutics market report table of contents includes:

1. Executive Summary

2. Bipolar Disorder Therapeutics Market Characteristics

3. Bipolar Disorder Therapeutics Market Trends And Strategies

4. Bipolar Disorder Therapeutics Market – Macro Economic Scenario

5. Global Bipolar Disorder Therapeutics Market Size and Growth

26. South America Bipolar Disorder Therapeutics Market

27. Brazil Bipolar Disorder Therapeutics Market on

28. Middle East Bipolar Disorder Therapeutics Market

29. Africa Bipolar Disorder Therapeutics Market

30. Bipolar Disorder Therapeutics Market Competitive Landscape And Company Profiles

Top Major Players: